Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:

1. MindMed’s Mission
2. Their Talent acquisition
3. The Progress of their different clinical trials
4. The future

Timestamps:
0:00 – Intro
1:59 – MindMed’s Mission
4:36 – MMED’s talent acquisition
7:24 – MindMed’s clinical trial progress
10:48 – Psychiatry department : Project Lucy
14:17 – Addiction department : Project Layla (18MC)
18:33 – Pain department: Project Angie to treat pain card
22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
23:43 – MindMed (MMED / MNMD) and its future plans

Enjoy!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #MNMD

Similar Posts

MindMed To Deliver Psychedelics Directly To The Brain? (MMED / MNMD)

MindMed To Deliver Psychedelics Directly To The Brain? (MMED / MNMD)

Listen, Videos

MindMed (MMED :NEO), (MNMD:NASDAQ), (MMQ: FRA) is testing the delivery of psychedelics compounds directly to the brain!?

What is the best way to take a psychedelic medicine? Is it in a format of a pill, a film strip which dissolves under the tongue, or maybe an injection? These are the standard delivery methods we’re all familiar with.
But what if we could deliver a psychedelic medicine directly to the brain, and thus negate any potentially negative side effects of the drug interacting with the body?
Answering this question is the purpose of a new MindMed partnership.

In this episode, we’ll explore MindMed’s new partnership with Nextage Therapeutics, their Brain Targeting Liposome System (BTLS), and it’s applications.

Enjoy the episode!

Link:
https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Website: https://thepsychedelicinvestor.com/
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MNMD #MindmedNews

Psychedelic stocks: the next BILLION dollar industry (2 mushroom stocks you MUST own in 2020)

Psychedelic stocks: the next BILLION dollar industry (2 mushroom stocks you MUST own in 2020)

Listen, Videos

Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Interview with Victoria and Joël, of Tandava Retreats

Interview with Victoria and Joël, of Tandava Retreats

Listen, Podcasts

Swati sits down with leaders from Kaivalya Kollectiv, “a multifaceted company focusing on psychedelic wellness, education”, and more. She speaks with Victoria Wueshner, a 5-MeO-DMT Facilitator and the Founder of FIVE, and Joël Brierre, CEO of Kaivalya Kollectiv.

Interview With Henri Sant-Cassia

Interview With Henri Sant-Cassia

Listen, Podcasts

In today’s episode of the Psychedelic Spotlight podcast, we spotlight Henri Sant-Cassia, Co-Founding Partner of The Conscious Fund, a leading investment fund in the medicinal psychedelics industry, focused on early stage ventures and psychedelic medicine that are helping to deliver better outcomes for mental health, addiction and pain.

More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

Listen, Videos

Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.

We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
So in this episode we are briefly going to run through them.

So what else can MindMed and MMED/MMEDF investors expect this year?

1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
-When will it launch?
-In what manner will it affect MindMed
-And how much it will influence MindMed’s stock price

2. Atai Life Sciences expected IPO how that’ll affect MindMed
– How will the IPO of another big rival will affect MMED/MMEDF?

3. Potential catalyst of Partnerships, Mergers and Acquisitions
-Coming directly from an Interview with JR Rahn and Kevin O’Leary

Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF